Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Lund University | OTHER |
Not provided
Not provided
Not provided
Not provided
The study aims to investigate pathophysiological changes in coagulation in relation to inflammation in patients with acute pancreatitis. Serum and plasma is sampled repeated days from admission. Analysis will be done after recruitment. Specific biomarkers accuracy for prediction of moderate and severer acute pancreatitis will be calculated.
Inclusion criteria:
Patients with acute pancreatitis admitted to Skåne University Hospital in Malmö
Acute pancreatitis is defined as minimum 2 out of following: amylase levels >3 times upper reference limit, clinical signs of acute pancreatitis, imaging findings of acute pancreatitis)
Exclusion criteria:
<18 years of age
>72 hours from onset of symptom until first sampling
Patients with immunosuppression or autoimmune diseases are excluded from som parts of the study.
Methods: Serum and plasma is sampled repeatedly during the hospital admission. Pre defined protocols are used for data collections of relevant clinical information.
Specific aspects of inflammation, thrombin generation, platelet function and Microparticles will be analysed in serum or plasma during the first consecutive days of acute pancreatitis.
Biomarkers for severe disease as well as correlation between inflammation and coagulopathy will be investigated.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Mild acute pancreatitis | Groups are defined by the Revised Atlanta classification. Anticipated 60% mild, 30% moderate and 10% severe patients |
| |
| moderately severe acute pancreatitis | Groups are defined by the Revised Atlanta classification. Anticipated 60% mild, 30% moderate and 10% severe patients |
| |
| severe acute pancreatitis | Groups are defined by the Revised Atlanta classification. Anticipated 60% mild, 30% moderate and 10% severe patients |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Exploratory for different markers | Diagnostic Test | Test biomarkers for development of mild, moderate or severe disease |
|
| Measure | Description | Time Frame |
|---|---|---|
| Severe acute pancreatitis | According to Revised Atlanta which is a consensus document where organ failure (defined by modified Marshall score) less than 48hours or signs of local complications on CT scan defines severity. This is not a scale but a generally used definition according to the paper: Banks PA, et al. Classification of acute pancreatitis-2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013;62(1):102-11. | 14 days |
| Measure | Description | Time Frame |
|---|---|---|
| Moderately Severe Acute Pancreatitis | According to Revised Atlanta which is a consensus document where organ failure (defined by modified Marshall score) less than 48hours or signs of local complications on CT scan defines severity. This is not a scale but a generally used definition according to the paper: Banks PA, et al. Classification of acute pancreatitis-2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013;62(1):102-11. |
Not provided
Inclusion Criteria: Acute Pancreatitis, accept informed consent -
Exclusion Criteria: More than 72h from onset of symptoms until first sample, patient already included once
-
Not provided
Not provided
Not provided
All patients admitted with Acute Pancreatitis at Skåne University Hospital in Malmö
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sara Regnér, MD, PhD | Region Skåne and Lund University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Skåne University Hospital | Malmö | Skåne County | 20502 | Sweden |
After publications. Upon request from other researchers or publishers with scientific interest and in accordance with GDPR regulations
During 2023
Upon request from other researchers or publishers with scientific interest and in accordance with GDPR regulations
Not provided
Not provided
| ID | Term |
|---|---|
| D010195 | Pancreatitis |
| ID | Term |
|---|---|
| D010182 | Pancreatic Diseases |
| D004066 | Digestive System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Serum and plasma. For some patients alveolar fluid.
| 14 days |